Clinical Trial Search

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants

Primary: Number of Phase I Participants Experiencing Toxicity — 1; 3 Participants

Primary: Progression-free Survival — 2.1; NA years — p=0.015

Primary: Total Number of Participants Who Experienced Acute Treatment Related Adverse Events — 52 Participants

Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…

Primary: Number of Participants Evaluated for Toxicity — 33 Participants

Primary: Complete Response Rate After Remission Induction — 66 percentage of participants

Primary: Event-free Survival — 16 Participants

Primary: 1 Year Progression Free Survival (PFS) — 58 Percentage of participants

Primary: Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year — 28 Participants

Primary: Overall Survival — 0; 0 Proportion of participants

Primary: Progression Free Survival — 39 days

Primary: BICR-Assessed Objective Response Rate (ORR) — 6.4; 26.3 Percentage of participants

Primary: Median Progression Free Survival (PFS) — 13.8 years

Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion

Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr

Primary: Neuropsychological Performance Change — -0.27; -0.17 units on a scale

Primary: Event-free Survival — 1; 1; 0; 0 participants

Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…

Primary: Complete Remission — 10 participants

Primary: Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL)…

Primary: Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) — 67.5; 76.2 percentage of participants

Primary: Frequency of Grade 3 or Higher Adverse Events — 0 number of occurrences

Primary: 2-yr Overall Survival — 0.70 probability

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects

Primary: Adverse Events Assessment — 6; 3; 3 Participants

Primary: Overall Survival — 28.5; 25.3 months — p=0.2853

Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg

Primary: Change in CSF Concentrations of Neopterin After 12 Weeks — 0.1; 0.3 nmol/L